Major Role for Amphotericin B–Flucytosine Combination in Severe Cryptococcosis
2008

Amphotericin B and Flucytosine Combination for Severe Cryptococcosis

Sample size: 208 publication 10 minutes Evidence: high

Author Information

Author(s): Dromer Françoise, Bernede-Bauduin Claire, Guillemot Didier, Lortholary Olivier

Primary Institution: Institut Pasteur, Paris, France

Hypothesis

What are the optimal therapeutic strategies for severe cryptococcosis?

Conclusion

Induction therapy with amphotericin B and flucytosine for at least 14 days is recommended for patients with high fungal burden.

Supporting Evidence

  • Combination therapy reduced treatment failure at 2 weeks compared to other regimens.
  • High serum antigen titer was associated with treatment failure.
  • Patients with meningoencephalitis had better outcomes with the combination therapy.

Takeaway

This study found that a combination of two medicines works better for treating a serious fungal infection in the brain than using just one medicine.

Methodology

The study analyzed data from 208 patients with culture-proven cryptococcosis treated in French hospitals, focusing on treatment outcomes at 2 weeks and 3 months.

Potential Biases

The observational nature of the study may introduce biases related to treatment choices.

Limitations

The study design may not provide equal figures in each treatment group, which could influence significance.

Participant Demographics

Majority were HIV-positive male patients with meningoencephalitis.

Statistical Information

P-Value

p<0.001

Confidence Interval

OR [95%CI] = 4.43 [1.21–16.23], p = 0.025

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pone.0002870

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication